A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Single Oral Doses of NSA-789 on Auditory P50 Suppression in Nonsmoking Patients With Stabilized Schizophrenia.

Trial Profile

A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Single Oral Doses of NSA-789 on Auditory P50 Suppression in Nonsmoking Patients With Stabilized Schizophrenia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2009

At a glance

  • Drugs NSA 789 (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 May 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 May 2009 Additional location (USA) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top